The role of circulating PCSK9 in promoting hypercholesterolemia is strongly supported by preclinical experiments and clinical trials, where monoclonal antibodies (mAbs) directed against the LDLR binding site of PCSK9 efficiently reduce LDL-C levels3. Here, LDLR is linked to familial hypercholesterolemia.